AT-300 (Akashi Therapeutics/State University of New York at Buffalo) | Interleukin Related interleukin-related.com

Product Name :
AT-300 (Akashi Therapeutics/State University of New York at Buffalo)

Search keywords :
GsMTx4

drugId :
null

Target Vo:
Ion channels

Target Vo Short Name :
Ion channels

Moa_Name:
Ion channels antagonists

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
The State University of New York

Active Company_Name :

Active Indication_Name:

In Active Indication_Name:
Muscular Dystrophy, Duchenne

Termination Status :
Preclinical

China Termination Status :

Highest Status:
Pending

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
xCT Mouse mAb References
Emapalumab References
Phospho-MSK1 (Ser360) Antibody: Phospho-MSK1 (Ser360) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 90 kDa, targeting to Phospho-MSK1 (Ser360). It can be used for WB,ICC/IF,IP assays with tag free, in the background of Human, Mouse, Rat, Hamster.

Author: Interleukin Related

Related Posts